Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …

Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …

Purpose: KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal
adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to …

Pancreatic cancer is a genetic disease, and the recurrent genetic alterations characteristic of
pancreatic cancer indicate the cellular processes that are targeted for malignant …

The biology of solid tumors is strongly determined by the interactions of cancer cells with
their surrounding microenvironment. In this regard, pancreatic cancer (pancreatic ductal …

NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to
HER3, leading to heterodimerization with other HER/ERBB kinases, increased downstream …

Despite the development of second-generation antiandrogens, acquired resistance to
hormone therapy remains a major challenge in treating advanced prostate cancer. We find …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of cancer with a dismal
prognosis. The lack of symptoms in the early phase of the disease makes early diagnosis …